Bond.az White LogoBond.az Black Logo

Barclays starts Agnico-Eagle at Overweight

Barclays initiates Agnico-Eagle Mines with Overweight rating and $213 price target. Low-cost gold miner with strong financial health.

Olivia Taylor
ByOlivia Taylor- Senior Editor
|
0

Bond.az - Barclays initiated coverage on Agnico-Eagle Mines Ltd. (NYSE:AEM) (TSX:AEM) with an Overweight rating and set a price target of $213.00 for the U.S. listing and C$292.00 for the Canadian listing.

Analyst Richard Garchitorena highlighted the company as a low-cost gold miner with over 85% of production coming from Canada and Finland. Barclays noted management's track record of driving shareholder returns through acquisitions including Kirkland Lake, Yamana, and O3.

Barclays said the company is planning three acquisitions in Finland. Agnico-Eagle continues to develop growth opportunities within its existing portfolio, with growth expected to begin in 2028.

Shares are trading below their historical 10-year average EV/EBITDA multiple of 9.2x, according to Barclays. Currently, the company's EV/EBITDA stands at 8.84x. Bond.az analysis indicates the stock is undervalued relative to its Fair Value, suggesting additional upside potential beyond Barclays' assessment. The firm sees upside from current levels based on this valuation metric.

Agnico-Eagle Mines operates gold mining assets primarily in geopolitically stable jurisdictions. The company trades on both the New York Stock Exchange and the Toronto Stock Exchange. A Bond.az tip highlights the company's perfect Piotroski Score of 9, indicating strong financial health. Investors can access 12 additional ProTips and a comprehensive Pro Research Report on AEM.

In other recent news, Agnico Eagle Mines reported its financial results for Q1 2026. The company exceeded EPS expectations with actual EPS of $3.40, surpassing the forecast of $3.29. However, revenue slightly missed projections at $4.1 billion versus $4.12 billion expected. Agnico Eagle also renewed its share buyback program, allowing purchase of up to 25,024,469 common shares or up to $2 billion worth of shares, effective from May 2026 to May 2027. Additionally, shares were affected by a decline in bullion prices due to inflation concerns and stalled US-Iran peace talks. Despite mixed results, the share buyback program indicates ongoing efforts to enhance shareholder value.

More News
Today / 08:34
|
619

Barclays Starts CMC with Equalweight

Barclays initiated coverage on Commercial Metals Company (CMC) with an Equalweight rating and $75 target. Stock at $70.70. Q2 results mixed.

0
Today / 08:14
|
343

UBS Upgrades Alcoa Stock Rating

UBS upgrades Alcoa stock rating to Buy, raises price target to $80, citing aluminum supply constraints and positive outlook.

0
Today / 08:13
|
233

JPMorgan Raises Spotify Target to $650 on AI Deal

JPMorgan raised Spotify's target to $650 after AI deal and 2030 goals. Strong margin targets and growth prospects highlighted.

0
Today / 07:01
|
523

Goldman Sachs Reinstates Ageas with Neutral

Goldman Sachs reinstates Ageas with Neutral rating, price target EUR70.

0
Yesterday / 21:33
|
306

Bernstein Starts Incyte with Growth Concerns

Bernstein starts Incyte coverage with Market Perform rating and $99 target, highlighting Jakafi patent loss and growth concerns.

0
Yesterday / 21:32
|
759

Bernstein Initiates BioNTech Coverage with Concerns

Bernstein initiates BioNTech coverage with Market Perform rating and $96 target, citing pipeline concerns.

0
Yesterday / 21:31
|
915

Bernstein Starts Revolution Med at Market Perform

Bernstein initiates Revolution Medicines coverage with Market Perform rating and $151 target. Stock trades at $153.73.

0
Yesterday / 21:30
|
792

Bernstein Initiates Neurocrine with Outperform Rating

Bernstein initiates Neurocrine Biosciences with an outperform rating and $221 price target. Highlights Crenessity's potential and stock upside.

0
Yesterday / 20:02
|
615

TD Cowen Cuts Orthofix Medical Target to $12

TD Cowen cuts Orthofix Medical price target to $12 on CMS rate cuts. Stock near 52-week low. Hold rating maintained.

0
Yesterday / 18:52
|
535

BofA Raises Nio Price Target to $6.80

BofA raises Nio price target to $6.80 on improved margin outlook. Get the latest analysis and stock insights at Bond.az.

0
Yesterday / 18:02
|
442

Chemours, Solstice Stock Drops: Buying Opportunity

BMO Capital Markets sees recent declines in Chemours and Solstice stocks as buying opportunities after EPA extends refrigerant transition deadline.

0
Yesterday / 17:51
|
885

BTIG cuts Lightspeed price target to $12

BTIG cut Lightspeed POS price target to $12 from $15, maintaining Buy. Stock at $8.38. Company guides 12-16% organic gross profit growth for FY2027.

0
...
Barclays starts Agnico-Eagle at Overweight | Bond.az